Is it appropriate to treat an 88‑year‑old female with permanent atrial fibrillation, CHADS₂‑VASc (stroke risk) score of 6, HAS‑BLED (bleeding risk) score of 2, moderate‑severe mitral stenosis, and recent acute decompensation with low‑dose furosemide every other day while withholding anticoagulation?

Anticoagulation Should Be Strongly Considered Despite Fall Risk in This High-Stroke-Risk Patient

The decision to withhold anticoagulation in this 88-year-old woman with atrial fibrillation, a CHA₂DS₂‑VASc score of 6, and moderate-severe mitral stenosis is inappropriate based on current guidelines, and warfarin anticoagulation should be strongly reconsidered. 1

Critical Issue: Mitral Stenosis Changes the Anticoagulation Landscape

This patient has moderate-severe mitral stenosis, which fundamentally alters the anticoagulation decision:

• Warfarin is the only recommended anticoagulant for patients with AF and moderate-to-severe mitral stenosis. 1 Direct oral anticoagulants (DOACs) are contraindicated in this population due to lack of evidence and potential harm. 1, 2, 3

• The 2014 AHA/ACC/HRS guidelines explicitly state that for patients with AF and prior stroke, TIA, or CHA₂DS₂‑VASc score ≥2, oral anticoagulants are recommended (Class I, Level A for warfarin). 1 This patient's score of 6 places her at extremely high stroke risk—approximately 9-15% annual stroke risk without anticoagulation. 1

• The presence of rheumatic or significant mitral stenosis with AF mandates anticoagulation regardless of CHA₂DS₂‑VASc score. 1, 4, 5 The guidelines classify this as "highest risk for stroke." 1

Reassessing the Fall Risk Concern

The HAS-BLED score of 2 indicates moderate, not high, bleeding risk:

• A HAS-BLED score of 2 does not contraindicate anticoagulation. 1 Scores ≥3 warrant caution and closer monitoring, but even then, anticoagulation is not automatically contraindicated. 1

• Fall risk alone should not be used to withhold anticoagulation. 6, 7 Studies show that a patient would need to fall approximately 295 times per year for the bleeding risk from falls to outweigh the stroke prevention benefit of anticoagulation in high-risk AF patients. 6

• The 2024 ESC guidelines emphasize that "assessment and management of modifiable bleeding risk factors is recommended in all patients eligible for oral anticoagulation" but explicitly state that "use of bleeding risk scores to decide on starting or withdrawing oral anticoagulation is not recommended." 1

The Stroke Risk Far Outweighs Bleeding Risk

With a CHA₂DS₂‑VASc score of 6 plus moderate-severe mitral stenosis:

• Annual stroke risk without anticoagulation: 12-18% 1, 4, 5
• Annual major bleeding risk with warfarin: 2-4% 1
• Warfarin reduces stroke risk by approximately 64% in this population 1

The net clinical benefit strongly favors anticoagulation. 1

Specific Recommendations for This Patient

Anticoagulation Strategy

Initiate warfarin with target INR 2.0-3.0: 1

• This is the only evidence-based anticoagulant for AF with moderate-severe mitral stenosis 1
• Monitor INR weekly during initiation, then monthly when stable 1
• Ensure time in therapeutic range (TTR) >70% for optimal efficacy and safety 1

Fall Risk Mitigation (Rather Than Anticoagulation Avoidance)

• Implement comprehensive fall prevention strategies in the nursing facility 1, 7
• Physical therapy assessment and environmental modifications 7
• Medication review to minimize sedating drugs 7
• Consider hip protectors if appropriate 6

Diuretic Management

Low-dose furosemide every other day is reasonable for symptom management of the recent decompensation: 1, 8

• The FDA label supports starting doses of 20-80 mg daily for edema, with careful titration 8
• Every-other-day dosing is appropriate for mild volume overload 8
• Monitor for hypovolemia, electrolyte disturbances, and hypotension, which could increase fall risk 1, 8

Common Pitfalls to Avoid

1. Do not use DOACs in this patient. Despite emerging data suggesting possible safety 2, 3, current guidelines explicitly contraindicate DOACs in moderate-severe mitral stenosis. 1 The INVICTUS trial showed warfarin was superior to rivaroxaban in this population. 3

2. Do not substitute aspirin for anticoagulation. Aspirin provides minimal stroke protection in AF (approximately 20% risk reduction vs. 64% for warfarin) and does not significantly reduce bleeding risk compared to anticoagulation. 1

3. Do not allow the "permanent" AF designation to influence anticoagulation decisions. Guidelines explicitly state that stroke risk assessment should be independent of AF pattern (paroxysmal, persistent, or permanent). 1

4. Recognize that advanced age and nursing home residence are not contraindications to anticoagulation. 6, 7 The decision should be based on net clinical benefit, life expectancy, and patient/family goals of care through shared decision-making. 1

Shared Decision-Making Discussion Points

Revisit the goals of care conversation with the patient and family: 1

• Present the actual stroke risk (12-18% annually) vs. bleeding risk (2-4% annually) 1, 4
• Discuss that strokes in AF are typically more severe and disabling than in non-AF patients 1, 5
• Acknowledge the burden of INR monitoring but emphasize the substantial mortality and morbidity reduction 1
• If the family's primary concern is fall-related bleeding, emphasize that intracranial hemorrhage from falls on warfarin is rare and that stroke prevention benefit is substantial 6, 7

If anticoagulation is definitively refused after thorough shared decision-making, document this extensively and ensure the family understands the high stroke risk being accepted. 1